Wogonoside Mitigates Inflammation and Cell Proliferation via Modulation of NF-κB Signalling Pathway in DMBA-Induced Mammary-Preclinical Model

Objectives: To hypothesis the effect of wogonoside against DMBA-induced Breast Cancer (BC) via TNF-α induced NF-κB signaling pathway a molecular appraoch. Materials and Methods: A 25 mg/kg Body Weight (BW), DMBA mixed dosage was used to produce BC with 1 mL olive oil by subcutaneous injection. We observed reduced body weight, elevated hepatic marker (AST, ALP, ACP and ALT), phase I (Cyt-b5 and Cyt-p450) and lipid peroxidative (TBARS and LOOH) markers and reduced antioxidant and xenobiotic enzymes in DMBA induced cancer-bearing rats. Moreover, the molecular study revealed that up-regulation of, inflammatory (NF-κB p65, TNF-α, IL-6 and IL-1β) markers in DMBA treated cancer-bearing animals. Results: Oral supplementation of wogonoside substantially reverted back to normal levels of these DMBA-induced rats have biochemical and molecular indicators. Conclusion: Overall, these findings supported wogonoside anti-inflammatory and anti-cell proliferation activity against DMBA-induced breast cancer through modification of the NF-κB signaling pathway.